Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malariaSusan A. Charman, Jonathan L. Vennerstrom, J. Carl Craft et al.|Proceedings of the National Academy of Sciences|2011Cited by 379
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancerShikhar Sharma, Meghan Hattarki, Chi‐Yeh Chung et al.|Cell chemical biology|2023Cited by 72
Abstract 1130: First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulationShikhar Sharma, Thomas A. Paul, Jay H. Chung et al.|Cancer Research|2021Cited by 14
First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER plus breast cancer with KAT6A dysregulation.Shikhar Sharma, Thomas A. Paul, Jay H. Chung et al.|Cancer Research|2021Cited by 1